Informations générales (source: ClinicalTrials.gov)
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors
Interventional
Phase 1/Phase 2
Merck Sharp & Dohme LLC (Voir sur ClinicalTrials)
mars 2025
mars 2031
02 mars 2026
Researchers are looking for new ways to treat people with certain advanced solid tumors.
Advanced means the cancer has spread to other parts of the body and cannot be removed
with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the
blood or other body liquids. The main goal of this study is to learn about the safety of
MK-3120 and if people tolerate it.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Yohann LORIOT | 09/06/2026 13:15:08 | Contacter | ||
Critères
Tous
- Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has
received or been intolerant to all available treatments
- If human immunodeficiency virus (HIV) positive, has well controlled HIV on
antiretroviral therapy (ART)
- If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B
virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral
load
- If hepatitis C virus (HCV) infected, must have undetectable HCV viral load
Exclusion Criteria:
- Has active inflammatory bowel disease requiring immunosuppressive medication or
previous history of inflammatory bowel disease
- Has uncontrolled significant cardiovascular disease or cerebrovascular disease
- Has history of documented severe dry eye syndrome, severe Meibomian gland disease
and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
- Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or
require repeated drainage
- Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric
Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment
within the past 2 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active infection requiring systemic therapy, with exceptions
- History of (noninfectious) pneumonitis/interstitial lung disease that required
steroids or has current pneumonitis/interstitial lung disease
- Has HBV or HCV infection